StockIQpro
NASDAQ:RVMD

Revolution Medicines, Inc.

Track all markets on TradingView
Track all markets on TradingView

Revolution Medicines, Inc.'s revenue was $0 in fiscal 2025. Free cash flow was −$913.7M, and the diluted share count rose 13.3%.Summary generated from Revolution Medicines, Inc.'s SEC filings. Latest annual report filed Feb 25, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$0
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−58.1%
Debt / equityn/a
Free cash flow−$913.7M
FCF marginn/a
Share count change+13.3%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue29351200
Operating income−188−258−487−690−1,182
Net income−187−249−436−600−1,131
Free cash flow−154−235−358−568−914

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)